Devyser Diagnostics AB (publ) (DVYSR.ST)
SEK 117.0
(0.0%)
SEK 117.0
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -69.7 Million | -40.5 Million | -16.48 Million | 627 Thousand | 14.63 Million | 6.02 Million |
| Net Income | -53.6 Million | -45.95 Million | -20.72 Million | -10.91 Million | 7 Million | 519 Thousand |
| Depreciation & Amortization | 9.8 Million | 6.16 Million | 3.27 Million | 2.96 Million | 2.32 Million | 1.24 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -21.5 Million | 4.4 Million | 1.46 Million | -268 Thousand | 2.89 Million | 2.98 Million |
| Other non-cash items | 36.7 Million | 2.79 Million | 4.58 Million | 15.03 Million | 4.15 Million | 780 Thousand |
| Investing Cash Flow | -32 Million | -23.85 Million | -10.32 Million | -4.71 Million | -9.96 Million | -5.06 Million |
| Investments in PPE | -32 Million | -25.79 Million | -8.79 Million | -3.41 Million | -9.31 Million | -5.06 Million |
| Acquisitions | - | 1.93 Million | -1.52 Million | -225 Thousand | - | - |
| Investment purchases | - | - | -1.52 Million | -1.07 Million | -652 Thousand | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -20.5 Million | -1000.00 | - | 1000.00 | - | - |
| Financing Cash Flow | -200 Thousand | 48.94 Million | 395.92 Million | 2.26 Million | -1.86 Million | -974 Thousand |
| Debt repayment | -100 Thousand | -693 Thousand | -8.07 Million | -267 Thousand | -56 Thousand | -326 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 5.6 Million | 52.27 Million | 406.72 Million | 4.88 Million | 137 Thousand | 154 Thousand |
| Other Financing Activities | -5.7 Million | -100 Thousand | -1000.00 | 1000.00 | - | - |
| Accounts receivables | -15.7 Million | -8.38 Million | -2.26 Million | -8.22 Million | -2.17 Million | 3.75 Million |
| Accounts payables | 4.7 Million | 16.18 Million | 5.02 Million | 9.54 Million | 4.81 Million | -611 Thousand |
| Inventory | -10.5 Million | -3.39 Million | -1.28 Million | -1.58 Million | 258 Thousand | -157 Thousand |
| Other working capital | 4.7 Million | - | - | - | - | - |
| Cash at beginning of period | 363.6 Million | 377.63 Million | 8.34 Million | 10.37 Million | 7.53 Million | 7.55 Million |
| Cash at end of period | 262.89 Million | 363.6 Million | 377.63 Million | 8.34 Million | 10.37 Million | 7.53 Million |
| Capital Expenditure | -32 Million | -25.79 Million | -8.79 Million | -3.41 Million | -9.31 Million | -5.06 Million |
| Effect of forex changes on cash | 1.3 Million | 1.4 Million | 173 Thousand | -216 Thousand | - | - |
| Net cash flow / Change in cash | -100.7 Million | -14.03 Million | 369.29 Million | -2.03 Million | 2.84 Million | -17 Thousand |
| Free Cash Flow | -101.7 Million | -66.29 Million | -25.28 Million | -2.78 Million | 5.31 Million | 957 Thousand |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -23.2 Million | -22.9 Million | -12.2 Million | -53.6 Million | -13.1 Million | -6 Million |
| Depreciation & Amortization | 5.8 Million | 5.6 Million | 5.4 Million | 9.8 Million | 3.2 Million | 2.6 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 4.4 Million | 900 Thousand | -11.4 Million | -21.5 Million | -800 Thousand | -5 Million |
| Other non-cash items | 5.9 Million | 10.7 Million | 23.9 Million | 36.7 Million | 4.2 Million | 4.7 Million |
| Investing Cash Flow | -16.9 Million | -10.8 Million | -27.5 Million | -32 Million | -9.7 Million | -2.5 Million |
| Investments in PPE | -4 Million | -10.7 Million | -27.6 Million | -32 Million | -9.7 Million | -2.5 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 100 Thousand | -100 Thousand | 100 Thousand | - | - | - |
| Financing Cash Flow | -1.6 Million | 12.5 Million | -3.1 Million | -200 Thousand | -1.8 Million | 2.2 Million |
| Debt repayment | - | -100 Thousand | - | -100 Thousand | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 2.3 Million | 16.39 Million | 800 Thousand | 5.6 Million | - | 4.3 Million |
| Other Financing Activities | -3.9 Million | -3.79 Million | -100 Thousand | - | - | -100 Thousand |
| Accounts receivables | 6.2 Million | -800 Thousand | -9.4 Million | -15.7 Million | -600 Thousand | -4.8 Million |
| Accounts payables | -3.4 Million | 3.5 Million | 1.9 Million | 4.7 Million | 4.8 Million | 700 Thousand |
| Inventory | 1.6 Million | -1.8 Million | -3.9 Million | -10.5 Million | -5 Million | -900 Thousand |
| Other working capital | 4.4 Million | 3.5 Million | - | - | - | - |
| Cash at beginning of period | 201 Million | 215 Million | 262.89 Million | 363.6 Million | 287.9 Million | 303 Million |
| Cash at end of period | 171.4 Million | 201 Million | 215 Million | 262.89 Million | 262.89 Million | 287.9 Million |
| Capital Expenditure | -4 Million | -10.7 Million | -27.6 Million | -32 Million | -9.7 Million | -2.5 Million |
| Effect of forex changes on cash | - | 100 Thousand | -800 Thousand | 1.3 Million | 300 Thousand | -800 Thousand |
| Net cash flow / Change in cash | -29.6 Million | -14 Million | -47.89 Million | -100.7 Million | -25 Million | -15.1 Million |
| Free Cash Flow | -16.9 Million | -26.7 Million | -44.1 Million | -101.7 Million | -23.4 Million | -16.4 Million |
1798
3630
2916
ALTX
AVCRF
PSYBF